A Study of WF 10 IV Solution in Patients With Advanced HIV Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if it is safe and effective to give WF 10 (TCDO) to
patients with advanced HIV disease who cannot or will not take zidovudine, didanosine,
zalcitabine, or stavudine. This study also examines how TCDO affects the levels of HIV in the
body. TCDO is a solution delivered through a vein.